Figure 1
From: Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer
NV1066 infects, replicates and demonstrates effective growth inhibition in multiple TNBC cell lines. (a) GFP expression confirmed viral infection as early as 24 h. Viral infectivity is dose dependent (shown in upper panel for day 1) and time dependent (shown at an MOI of 0.1 for days 1 and 3 in the lower panel). (b) Survival curves of infected cells compared with uninfected controls were calculated using a lactate dehydrogenase assay using different MOIs of NV1066 (0.01, 0.1, and 1). All cytotoxicity assays were carried out for 7 days in all five TNBC cell lines. MOI, Multiplicity of infection. (c) NV1066 replicates in all TNBC cell lines efficiently. Standard viral plaque assay was performed to determine the replication efficacy of NV1066 in five TNBC cell lines. Highest viral titer of 5 × 106 PFU, a 170-fold increase from initial viral dose at an MOI of 1.0 within 3 days of viral infection. Data represent means±s.e.m.
